OptimizeRx: Pivoting to the 'Operating System for Pharma Marketers' Amid Concentrated Top-Line Pain
A Quarter of Contrasts
OptimizeRx's second quarter 2026 was a study in juxtaposition. Revenue of $20.5M fell 30% year-over-year, yet adjusted EBITDA of $4.9M beat consensus and gross margins expanded to 75% — the highest in the company's history. The story is one of execution against a truncated top line: large customers are consolidating spend, but the underlying operating model is proving far more profitable than ever before.
Our results reflect continued margin expansion, disciplined operational execution, and the resilience of our operating model despite a health care marketing environment that remains dynamic.
The revenue decline is not broad-based. CFO Edward Stelmakh attributed it to a channel mix shift away from low-margin managed services and one major client that generated zero revenue this quarter. Indeed, the company has been deliberately exiting managed services since the Medicx acquisition, favoring higher-margin, more durable revenue streams. This is a strategic choice that has compressed the top line but transformed the profit profile.
“The revenue reduction was largely contained a limited number of large customers that utilized the lower margin managed services in 2025.” — Edward Stelmakh, Chief Financial Strategy Officer · 2026-08-12The AI/DSP Bet
Where the company is placing its future is unmistakable: the intelligent activation platform (DAP) grew over 30% year-over-year, and software subscription revenue rose 25%. The spotlight, however, is on the new product launches — DeepIntent's integration as the first healthcare DSP to connect directly to an authenticated EHR network, the natural-language audience builder (NLAB), and CopayQ. CEO Steve Silvestro framed these as proof of a strategic evolution:
We are evolving beyond being solely a point-of-care marketing company into being the operating system for pharmaceutical marketers.
This pivot is designed to capture a larger share of programmatic healthcare spend — a market where 60% of buys now flow through DSPs. The DeepIntent partnership went live in the weeks after quarter-end, and management expects bid flow to ramp meaningfully. While too early to quantify, the strategic positioning is clear: instead of being a transaction-based point-of-prescribe vendor, OptimizeRx is embedding its data and inventory into the planning tools marketers already use. This aligns with the company's product innovation momentum and its ambition to become a recurring, subscription-led business.
Margin Expansion Is Real — and Sustainable?
The gross margin jump to 75% (from 61% a year ago) is striking. Management now guides to a sustained high-60% to low-70% range, a significant uplift from the low-60% historical band. The driver is a favorable channel mix — a combination of exiting low-margin services and a more selective approach to partner pricing. This is not a one-off; the company is deliberately managing the business to that margin profile.
Given the revenue contraction, operating leverage is also showing. Adjusted EBITDA of $4.9M on $20.5M revenue implies a 24% margin, up from ~20% a year ago. The balance sheet is improving too: debt was reduced to $16.7M after the quarter, with a $10M buyback approved and a 10b5-1 plan in place. This capital discipline is notable given the stock's 90-day bounce of +25.8% and its still-distressed valuation.
Gross MarginCFO Transition and 2027 Positioning
A planned leadership transition was announced: CFO Edward Stelmakh will step down effective 12/31/2026, with current CBO Andy D'Silva succeeding him and Heather Favazza promoted to Chief Accounting Officer. The orderly nature of the change — Stelmakh stays as strategic advisor through 2027 — signals confidence in the finance organization. This is a strategy officer level change, but it reinforces the company's focus on deepening its financial and operational bench as it scales the new platform model.
Looking to the back half, management reaffirmed FY26 revenue of $95-100M and adjusted EBITDA of $21-25M, implying a significant Q4 weighting (35-40% of full-year revenue). The major client that has been absent is not expected to return this year, but discussions have reopened. Meanwhile, the mid-tier and long-tail client base is growing 'at an accelerated rate,' according to Silvestro, providing a natural offset to top-20 concentration.
“We are seeing good growth in the mid-tier segment ... they are growing at a faster rate and starting off at a smaller base.” — Andrew D'Silva, Chief Operating Officer · 2025-11-07That comment from the May 2026 call echoed the ongoing theme: the company is deliberately diversifying away from the largest pharma accounts, which remain under pressure from MFN pricing dynamics and macro budget caution. The mid-tier opportunity is the growth engine, while the DSP integration is the long-shot that could double the addressable market.
Why It Matters
OptimizeRx is trading at roughly 1.1x forward revenue — a steep discount to its historical multiples, reflecting investor skepticism about the top-line trajectory. The Q2 report offers a counter-narrative: the company is now significantly more profitable per dollar of revenue, has a cleaner product portfolio, and is laying the groundwork for a step-change in programmatic distribution. If the DSP integration ramps as planned and mid-tier growth continues, the market may begin to price in a return to growth with much higher margins.
For now, the stock's 55% rally off its May low suggests investors are starting to believe the transformation. The key watch item remains the recovery of the large client and the revenue visibility into 2027. As Steve Silvestro put it, the company is entering 2027 'really, really nicely.' The numbers, for once, support the confidence.